Tuesday, June 09, 2020 3:31:59 PM
JL. you know the differences between the labels
WARNINGS AND PRECAUTIONS -----------------------
• In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. (5.1)
• LOVAZA may increase levels of low-density lipoprotein (LDL). Monitor LDL levels periodically during therapy. (5.1)
• Use with caution in patients with known hypersensitivity to fish and/or shellfish. (5.2)
• There is a possible association between LOVAZA and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)
Can you explain to me why you pay so much more than poster North for Vascepa. ?
The main reason I think I have a far lower co pay than you ( no where as good as North ) is that Kaiser has determined its cost effective for them to have me on Vascepa ....to reduce their risk of having to pay for most of a PCI .
Back back to your original argument .....competition . GV to be more expensive than G Lovaza . Doubt if it will be a huge difference . There is a Marine market for G Vascepa ...for all those who dont want to take statins or can not tolerate a higher dose of the statin they are on to control elevated LDL....but still need to lower very high TG's.
Hopefully it won't come to that . Singer will ride to the rescue ...in that we trust .
Kiwi
WARNINGS AND PRECAUTIONS -----------------------
• In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. (5.1)
• LOVAZA may increase levels of low-density lipoprotein (LDL). Monitor LDL levels periodically during therapy. (5.1)
• Use with caution in patients with known hypersensitivity to fish and/or shellfish. (5.2)
• There is a possible association between LOVAZA and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)
Can you explain to me why you pay so much more than poster North for Vascepa. ?
The main reason I think I have a far lower co pay than you ( no where as good as North ) is that Kaiser has determined its cost effective for them to have me on Vascepa ....to reduce their risk of having to pay for most of a PCI .
Back back to your original argument .....competition . GV to be more expensive than G Lovaza . Doubt if it will be a huge difference . There is a Marine market for G Vascepa ...for all those who dont want to take statins or can not tolerate a higher dose of the statin they are on to control elevated LDL....but still need to lower very high TG's.
Hopefully it won't come to that . Singer will ride to the rescue ...in that we trust .
Kiwi
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
